News

Carl Zeiss Meditec introduces new optical coherence tomography platforms that span the full spectrum of multi-modality imaging for glaucoma and retinal disease.

Though the association of aspirin use and age-related macular degeneration is controversial, the totality of evidence suggests there is no major harmful effect of aspirin use.

Results from studies of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration can be interpreted in a variety of ways, depending on the baseline bias of the individual.

Quantel Medical has received FDA 510(k) market clearance of its ophthalmic laser system (SupraScan 577 Laser) for treating a wide range of retinal diseases.

Recently introduced microinvasive glaucoma surgery procedures are easy enough to be performed by cornea specialists, but the need for close surveillance of the patient with glaucoma must be kept in mind.

There are a variety of new diagnostic tests for dry eye and a number of reasons to incorporate these technologies into practice.

The Ophthalmology Innovation Summit provides a forum for the leaders of ophthalmology to look at all aspects of the innovation process to create additional innovation and to circumvent issues that hinder that innovation.

Quantel Medical and Iridex have signed a global patent licensing agreement that gives Quantel access to Iridex's MicroPulse technology.

Heidelberg Engineering has received FDA clearance for its MultiColor scanning laser imaging as a new dimension in multi-modality fundus imaging with the Spectralis product family.

A new wavefront-guided LASIK procedure provides superior cylinder correction, better uncorrected visual acuity outcomes, and slightly higher patient satisfaction.

Preliminary results of a preclinical study investigating the effect of peripheral collagen crosslinking on the limbal stem cells provide some reassurance about the safety of the technique.

EyeGate Pharma’s broad iontophoresis patent portfolio for corneal collagen cross-linking will be held as exclusive license by Avedro Inc. Delivery approach provides potential additional benefits to current formulation.

Prevent Blindness America offers free educational materials to help the public, educators, and health professionals address diabetes and its visual consequences.

In a pilot phase II study, an intracanalicular plug (OTX-TP2, Ocular Therapeutics) shows promise for lowering IOP and increasing compliance with the treatment regimen.

Mitomycin C following wavefront-guided PRK for high myopia had no dose-dependent effect on haze scores throughout the study.

Nicox S.A. announced the U.S. launch of a point-of-care diagnostic test (AdenoPlus) that aids in the differential diagnosis of acute conjunctivitis.

SARcode Bioscience Inc. announced the topline results from OPUS-1, a pivotal phase III study of lifitegrast ophthalmic solution 5.0% for the treatment of dry eye disease.

Current multifocal IOLs have some limitations that in specific situations are overcome with the dual-optic accommodating IOL (Synchrony, Abbott Medical Optics).

The Glaucoma Foundation has announced George L. Spaeth, MD, as the 2012 recipient of the foundation’s Dr. Robert Ritch Award for Innovation and Excellence in Glaucoma.

A new strategy that uses the femtosecond laser to make a side cut for postLASIK re-treatment may reduce the incidence of epithelial ingrowth.

Antibiotic injections following cataract surgery were found to reduce risk of postop endophthalmitis by 22-fold.

The FDA advises health-care professionals to follow up with patients for whom they administered an injectable product purchased from or produced by NECC.

The FDA has approved ocriplasmin (Jetrea, ThromboGenics) for the treatment of symptomatic vitreomacular adhesion (VMA).

A Canadian trial including 120 subjects is investigating the safety and efficacy of an acrylic, foldable, single-piece, angle-supported phakic IOL (AcrySof Cachet, Alcon).

FCI Ophthalmics has received 510(k) clearance for a pushed monocanalicular nasolacrimal intubation stent (Masterka).

The FDA has approved cysteamine ophthalmic solution (Cystaran, Sigma-Tau Pharmaceuticals) 0.44% for corneal cystine crystal accumulation in patients with cystinosis.

The FDA has cleared the additional indication of corneal flap creation in refractive surgical procedures for a femtosecond laser platform (LenSx Laser, Alcon).

A video description of Cataract Surgery: Telling It Like It Is!, cataract meeting organized by Robert H. Osher, MD.